Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma

Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relap...

Descripción completa

Detalles Bibliográficos
Autores: Gutierrez, Antonio, Bento, Leyre, Novelli, Silvana, Martin, Alejandro, Gutierrez, Gonzalo, Queralt Salas, Maria, Bastos-Oreiro, Mariana, Perez, Ariadna, Hernani, Rafael, Cruz Viguria, Maria, Lopez-Godino, Oriana, Montoro, Juan, Piñana, Jose Luis, Ferra, Christelle, Parody, Rocio, Martin, Carmen, Español, Ignacio, Yáñez San Segundo, Lucrecia|||0000-0001-9925-3048, Rodriguez, Guillermo, Zanabili, Joud
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/25169
Acceso en línea:http://hdl.handle.net/10902/25169
Access Level:acceso abierto
Palabra clave:Mantle cell lymphoma
Allogeneic stem-cell transplantation
Non-relapse mortality
Acute graft-versus-host disease
Graft-versus-lymphoma effect
Target therapy
CAR-T cell therapy
Descripción
Sumario:Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3-4 aGVHD were associated with a higher NRM. Grade 3-4 aGVHD, donor type (mismatch non-related), and the time-period 2006-2020 were independently related to worse EFS. Patients from 1995-2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.

Similares en LA Referencia